Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guan Xing

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Leukemia & Lymphoma|December 10, 2020
No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisibJacqueline C Barrientos, Peter Hillmen, Gilles Salles, et al.
Clinical Rheumatology|May 19, 2024
miR-141-3p attenuates RSL3-induced ferroptosis and intestinal epithelial-mesenchymal transition via directly inhabits ZEB1 in intestinal Behçet's syndromeCheng-Cheng Hou, Hua-Fang Bao, Chun-Hui She, et al.
Japanese Journal of Clinical Oncology|August 29, 2020
Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemiaNoriko Fukuhara, Tomohiro Kinoshita, Kazuhito Yamamoto, et al.
British Journal of Haematology|June 14, 2021
A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel)Toby A Eyre, Gavin Preston, Huseini Kagdi, et al.
Zhonghua Nan Ke Xue = National Journal of Andrology|May 3, 2018
[Laparoscopic percutaneous extraperitoneal closure does not affect vas deferens orientation or testicular volume and perfusion]Le Xu, Can-Qiang Li, Xiao-Dong Chen, et al.
Leukemia & Lymphoma|July 28, 2021
Idelalisib immune-related toxicity is associated with improved treatment responseNina D Wagner-Johnston, Jeff Sharman, Richard R Furman, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 23, 2016
Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancerHong-Wei Luo, Qing-Biao Chen, Yue-Ping Wan, et al.
Leukemia & Lymphoma|November 9, 2018
Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trialsJacob D Soumerai, Ai Ni, Guan Xing, et al.
Leukemia & Lymphoma|December 10, 2020
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomasNina D Wagner-Johnston, Stephen J Schuster, Sven deVos, et al.
Molecular Medicine Reports|September 9, 2020
Functional classification of prostate cancer‑associated miRNAs through CRISPR/Cas9‑mediated gene knockoutFu-Neng Jiang, Yu-Xiang Liang, Wang Wei, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Leukemia & Lymphoma|December 10, 2020
No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisibJacqueline C Barrientos, Peter Hillmen, Gilles Salles, et al.
Clinical Rheumatology|May 19, 2024
miR-141-3p attenuates RSL3-induced ferroptosis and intestinal epithelial-mesenchymal transition via directly inhabits ZEB1 in intestinal Behçet's syndromeCheng-Cheng Hou, Hua-Fang Bao, Chun-Hui She, et al.
Japanese Journal of Clinical Oncology|August 29, 2020
Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemiaNoriko Fukuhara, Tomohiro Kinoshita, Kazuhito Yamamoto, et al.
British Journal of Haematology|June 14, 2021
A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel)Toby A Eyre, Gavin Preston, Huseini Kagdi, et al.
Zhonghua Nan Ke Xue = National Journal of Andrology|May 3, 2018
[Laparoscopic percutaneous extraperitoneal closure does not affect vas deferens orientation or testicular volume and perfusion]Le Xu, Can-Qiang Li, Xiao-Dong Chen, et al.
Leukemia & Lymphoma|July 28, 2021
Idelalisib immune-related toxicity is associated with improved treatment responseNina D Wagner-Johnston, Jeff Sharman, Richard R Furman, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 23, 2016
Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancerHong-Wei Luo, Qing-Biao Chen, Yue-Ping Wan, et al.
Leukemia & Lymphoma|November 9, 2018
Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trialsJacob D Soumerai, Ai Ni, Guan Xing, et al.
Leukemia & Lymphoma|December 10, 2020
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomasNina D Wagner-Johnston, Stephen J Schuster, Sven deVos, et al.
Molecular Medicine Reports|September 9, 2020
Functional classification of prostate cancer‑associated miRNAs through CRISPR/Cas9‑mediated gene knockoutFu-Neng Jiang, Yu-Xiang Liang, Wang Wei, et al.
Pageof 6